Top Markets
Coin of the day
Glenmark Life Sciences Limited Glenmark Life Sciences Limited

Glenmark Life Sciences Limited

GLS
株式のランク #7698
Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011,... Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011, specializes in the creation, manufacturing, and distribution of high-value active pharmaceutical ingredients (APIs). These APIs are utilized across a wide array of chronic therapeutic areas. The company's diverse portfolio includes compounds for managing cardiovascular diseases (e.g., Olmesartan, Rosuvastatin, Amiodarone), central nervous system conditions (such as Oxcarbazepine, Topiramate, Lacosamide), and diabetes (including Glimepiride, Teneligliptin, Linagliptin). Additionally, they produce APIs for pain management (Etoricoxib, Lornoxicam), gastro-intestinal disorders, anti-infective treatments, respiratory ailments, and anti-emetic applications, featuring products like Atovaquone, Fluconazole, and Esomeprazole Magnesium. Beyond API production, Glenmark Life Sciences offers contract development and manufacturing (CDMO) solutions to numerous multinational and specialty pharmaceutical firms. Operating as a subsidiary of Glenmark Pharmaceuticals Limited, the company exports its products worldwide, reaching markets in Europe, North America, Latin America, and Japan.
株価
$12.18
最終同期: 2025-02-17
時価総額
$1.49B
変化(1日)
4.21%
変化(1年)
0.00%
IN
取引 Glenmark Life Sciences Limited (GLS)

カテゴリー

Glenmark Life Sciences Limited(GLS)のEPS
2026 時点のEPS TTM: 0
Glenmark Life Sciences Limitedの最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Glenmark Life Sciences LimitedのEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。